Compare HCAI & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HCAI | PHGE |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | China | United States |
| Employees | N/A | 57 |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.7M | 7.0M |
| IPO Year | N/A | N/A |
| Metric | HCAI | PHGE |
|---|---|---|
| Price | $0.21 | $6.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $26.00 |
| AVG Volume (30 Days) | ★ 415.5K | 80.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $63.07 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.20 | $0.25 |
| 52 Week High | $10.97 | $8.50 |
| Indicator | HCAI | PHGE |
|---|---|---|
| Relative Strength Index (RSI) | 37.07 | 60.65 |
| Support Level | $0.20 | $0.41 |
| Resistance Level | $0.44 | $6.85 |
| Average True Range (ATR) | 0.02 | 0.72 |
| MACD | 0.00 | -0.08 |
| Stochastic Oscillator | 31.45 | 75.71 |
Huachen AI Parking Management Technology Holding Co Ltd is a comprehensive smart parking solutions and equipment structural parts provider. The company manufactures and offer various cubic parking garage products by employing various working principles, such as lifting and shifting, convenient lifting, vertical circulation, vertical lifting, plane moving, alley stacking, multi-layer cycle, horizontal cycle, and car lift.
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).